18 December 2015
Marinus Pharmaceuticals (NASDAQ:MRNS), which focuses on the development of treatments for epilepsy and neuropsychiatric disorders, said it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. After establishing eight weeks of baseline seizure frequency, patients randomized in the study undergo a two-week titration period followed by a twelve-week maintenance period. The company anticipates announcing top-line results from the study in mid-2016. In the Phase 2 study that was conducted in patients experiencing drug-resistant seizures for more than 25 years, ganaxolone met the primary endpoint and was safe and well-tolerated. Marinus shares closed at $6.12 on Tuesday with a 52-week spread of $4.52 – $20.72.
The stock increased 0.33% or $0.02 during the last trading session, hitting $6.14. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has declined 24.10% since May 14, 2015 and is downtrending. It has underperformed by 21.84% the S&P500.
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing neuropsychiatric therapeutics. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat patients with refractory focal onset seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II crossover clinical study to treat behaviors in Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to control acute seizures. It has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is based in Radnor, Pennsylvania.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024